Provided by Tiger Trade Technology Pte. Ltd.

INVESCO BIOTECHNOLOGY & GENOME ETF

95.07
-0.0300-0.03%
Post-market: 95.070.00000.00%19:30 EDT
Volume:18.13K
Turnover:1.72M
Market Cap:412.60M
PE:53.01
High:95.58
Open:95.58
Low:94.62
Close:95.10
52wk High:98.82
52wk Low:70.01
Shares:4.34M
Float Shares:4.34M
Volume Ratio:1.42
T/O Rate:0.42%
Dividend:1.33
Dividend Rate:1.40%
EPS(TTM):1.79
EPS(LYR):18.65
ROE:24.76%
ROA:0.08%
PB:1.67
PE(LYR):5.10

Loading ...

Political and General News Events from September 8

Reuters
·
Sep 08

【US Pre-Market】Middle East Energy Risks Escalate, Brent Crude Nears $100, Oil and Gas Stocks Rise; Novartis Plunges 13%

TradingKey
·
Sep 08

Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 08

Beneath the Surface, the Next Market Leaders are Getting Ready to Break Out, Says Morgan Stanley

Dow Jones
·
Sep 08

Alnylam price target raised to $260 from $230 at Jefferies

TIPRANKS
·
Sep 08

Ionis Pharma Tumbles After Heart Drug Fails Late-Stage Trial

Reuters
·
Sep 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

Why Amgen Stock is Dropping After Swiss Rival's Trial Setback

Dow Jones
·
Sep 08

Amgen Falls After Novartis Trial Setback, BMO Downgrade

Reuters
·
Sep 08

Stocks to Watch: Amgen, Nike, Bloom Energy

Dow Jones
·
Sep 08

Amgen Shares Down 5.4% Premarket; Rival Novartis Cholesterol Drug Fails Late-Stage Study

THOMSON REUTERS
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 07

Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs

Reuters
·
Sep 07

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

Stock News
·
Sep 07

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

Dow Jones
·
Sep 06

Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts

TIPRANKS
·
Sep 05

Royalty Pharma Announces Update on Novartis’ Phase 3 Topline Results for Pelacarsen

THOMSON REUTERS
·
Sep 05

Royalty Pharma - Expects to Recoup Investment and Earn Modest Return Despite Pelacarsen Failure

THOMSON REUTERS
·
Sep 05

Amgen EVP, CFO Thomas J.W. Dittrich Files Initial Beneficial Ownership Statement

Reuters
·
Sep 05